Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03569293 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
A Phase 3 study of Atopic Dermatitis, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 912
- Enrollment target
- 20
- Study locations
NCT03569293: Completed Phase 3 study of Atopic Dermatitis, sponsored by AbbVie.
NCT03569293 is a Phase 3 study of Atopic Dermatitis that has completed, run by AbbVie. The registered enrollment target is 912 participants, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03569293, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 912 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Primary Outcome
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scrat
Conditions Studied
Interventions
- DRUG Upadacitinib
- DRUG Placebo for Upadacitinib
Study Locations (20)
California
- Bakersfield Derma & Skin Cance /ID# 200433 - Bakersfield
- First OC Dermatology /ID# 201910 - Fountain Valley
- California Allergy and Asthma Medical Group /ID# 200727 - Los Angeles
- Allergy & Asthma Associates of Southern California /ID# 200733 - Mission Viejo
- Dermatology Clinical Trials /ID# 205876 - Newport Beach
- UC Davis /ID# 203622 - Sacramento
- Synergy Dermatology /ID# 200842 - San Francisco
- San Luis Derm and Laser Clinic /ID# 200372 - San Luis Obispo
- Stanford University /ID# 200440 - Stanford
- Care Access Research - Walnut Creek /ID# 200940 - Walnut Creek
Florida
- Clearlyderm Dermatology /ID# 208371 - Boca Raton
- Skin Care Research, LLC /ID# 200811 - Boca Raton
- Olympian Clinical Research /ID# 202914 - Clearwater
- Multi-Speciality Research Associates /ID# 213254 - Lake City
- GSI Clinical Research, LLC /ID# 200849 - Margate
Arizona
- Alliance Dermatology and MOHs /ID# 200375 - Phoenix
- Clear Dermatology & Aesthetics Center /ID# 201256 - Scottsdale
District of Columbia
- Foxhall Research Center /ID# 213682 - Washington D.C.
- Duplicate_George Washington Univ Med /ID# 200364 - Washington D.C.
Connecticut
- Dermatology Physicians of Connecticut /ID# 200928 - Shelton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 912 participants |
| Start Date | 2018-08-13 |
| Est. Completion | 2025-10-10 |
| Phase | Phase 3 |
What the finished NCT03569293 record still lists
NCT03569293 is an interventional study that assigns participants to a tested intervention. The registered 912 participants enrollment target is mid-sized for trials with a published cap, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (51% higher).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Upadacitinib is the first listed.
NCT03569293 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03569293 about?
NCT03569293 is a clinical study titled "Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)". The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
What is the current status of trial NCT03569293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 912 participants. The study started on 2018-08-13. Estimated completion is 2025-10-10.
What conditions does trial NCT03569293 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT03569293?
The interventions under investigation include: Upadacitinib (DRUG), Placebo for Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT03569293?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03569293 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03569293's enrollment target sits among peer trials
912 15th of 150 higher than 136 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI